Dr. Pan-Chyr Yang is currently a professor at the Department of Internal Medicine, College of Medicine, National Taiwan University, and Academician of Academia Sinica. He is also Vice President of the Institute for Biotechnology and Medicine Industry, Director of Taiwan AI Labs. He also serves as Juristic-Person Director at Diamond Biofund Inc., Taishin Life Insurance Co. Ltd., Everbright Biofund, and Independent Director at Realtek Semiconductor Corp. Dr. Yang is a world-renowned lung cancer researcher and has advocated for smart medicine and building a sustainable big-data platform for precision health in recent years.

Dr. Yang is a pioneer in his field as he has successfully applied ultrasound technology to the diagnosis of chest diseases. Since the early 2000s, he has conducted advanced research for female lung cancer in Taiwan and his work has been published in various international journals since then. During the pandemic, Dr. Yang and his team developed the ACE2-Fc decoy antibody to block virus infection, with their work being published by EMBO Molecular Medicine.

Dr. Yang holds a Ph.D. from the Graduate Institute of Clinical Medicine, National Taiwan University. He served as President of the university from 2013 to 2017, whereby, toward the end of his tenure, multiple subjects were ranked among the top 50 by the QS World University Rankings by Subject. Dr. Yang was a recipient of the 1993 Ten Outstanding Youth Award in Taiwan along with multiple Outstanding Research Awards from the National Science Council.

* Specialty sectors according to the Global Industry Classification Standard (GICS) classification, jointly developed by MSCI and the S&P Dow Jones Indices.